{"schema_version":"secwatch.filing_event.v1","accession":"0000926617-22-000054","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.076073+00:00","generated_at":"2026-06-22T00:29:28.933534+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aspira Women's Health Q3 product revenue up 26% to $2.0M; CFO departing Dec 1","bullets":["Q3 product revenue $2.037M (+26% YoY); Ova1Plus volume 5,524 (+29% YoY); gross margin 57%.","CFO Robert Beechey to depart Dec 1; will serve as consultant during successor search.","OvaWatch launch planned Q4 2022; ovarian cancer portfolio rebranded as OvaSuite.","Sponsored research agreement with Harvard Dana Farber, Brigham & Women's, and Medical Univ. of Lodz for endometriosis test.","Co-marketing with BioReference launched in Q4; raised $9M gross ($7.7M net) in public offering."],"urls":{"canonical":"https://secwatch.observer/filing/0000926617-22-000054","json":"https://secwatch.observer/filing/0000926617-22-000054.json","markdown":"https://secwatch.observer/filing/0000926617-22-000054.md","text":"https://secwatch.observer/filing/0000926617-22-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000092661722000054/0000926617-22-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000092661722000054/awh-20221110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:29:28.933534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31121db0cba0510a924ef3e98f024022f8a69a48","claim":"Aspira Women's Health Inc. reported the third quarter ended September 30, 2022 results: revenue $2,037,000.","evidence_excerpt":"wish Bob all the best in his future endeavors.”   Highlights of Third Quarter 2022 vs. Third Quarter 2021 · Product revenue for the three months ended September 30, 2022 was $2,037,000 compared to $1,617,000 for the same period in 2021, an increase of 26%. The number of Ova1Plus tests performed during the quarter increased 29% to 5,524 compared to 4,281 for the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661722000054/0000926617-22-000054-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$2,037,000"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}